Eloxx Pharmaceuticals

103 articles about Eloxx Pharmaceuticals

• CF Foundation Funds Expansion of Clinical Trial Program for Potential Nonsense Mutations Therapy

  3/29/2022

  Today, the Cystic Fibrosis Foundation announced an award to Eloxx Pharmaceuticals Inc. for up to $15.9 million in additional funding to support the expansion of its ongoing ELX-02 clinical program focused on developing therapies for people with CF who have nonsense mutations.

• Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

  3/29/2022

  Eloxx Pharmaceuticals, Inc. today announced that the Company has received additional funding of a Therapeutic Development Award of up to $15.9 million from the CF Foundation to support the ongoing ELX-02 clinical program.

• 

  Clinical Catch-Up: November 15-19

  11/22/2021

  With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.

• Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

  11/17/2021

  Eloxx Pharmaceuticals, Inc. today announced positive topline results from the monotherapy arms of its Phase 2 clinical trial of ELX-02 in Class 1 cystic fibrosis (CF) patients with at least one G542X nonsense allele mutation.

• Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

  11/9/2021

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three and nine months ended September 30, 2021 and provided a business update.

• Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs

  10/7/2021

  Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that it will host an Investor and Analyst call and webcast on Tuesday, October 12, 2021.

• Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

  10/5/2021

  Eloxx Pharmaceuticals, Inc., announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc., a specialty financing lender for life science and technology companies.

• Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations

  9/9/2021

  Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene for whom there are no effective disease modifying therapies.

• Eloxx Pharmaceuticals Appoints Chief Medical OfficerAli Hariri, M.D. to Lead Clinical Development Efforts for Company Pipeline

  9/8/2021

  Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced the appointment of Ali Hariri, M.D., as its Chief Medical Officer, overseeing clinical development efforts for the company’s promising pipeline of therapies to treat rare diseases.

• Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

  8/16/2021

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended June 30, 2021, and provided a business update.

• Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic FibrosisData Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021

  7/6/2021

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele.

• CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative

  5/27/2021

  New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

• Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents

  5/27/2021

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received an award of up to $2.6M from the Cystic Fibrosis Foundation.

• Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  5/18/2021

  Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the closing of an underwritten public offering of 38,333,334 shares of common stock at a public offering price of $1.35 per share.

• Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

  5/14/2021

  Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the pricing of an underwritten public offering of 33,333,334 shares of common stock at a public offering price of $1.35 per share

• Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

  5/13/2021

  Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.

• 

  Cystic Fibrosis: One Patient’s Story, Current Treatments and Exciting New Therapies on the Horizon

  5/11/2021

  “The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”

• Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update

  5/6/2021

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended March 31, 2021 and provided a business update.

• Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

  4/29/2021

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today announced the addition of a new study arm in the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele.

• Eloxx Pharmaceuticals Acquires Zikani Therapeutics

  4/1/2021

  Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA  and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with R ecessive Dystrophic  and Junctional Epidermolysis Bullosa (RDEB and JEB)